An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions Alone or in Partnership With Their MS Center
Latest Information Update: 13 Apr 2011
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Teva Neuroscience
- 13 Apr 2011 New trial record